Clinical trials: Recurrent/Metastatic Gastric Cancer
Gastro-Oesophageal Cancer
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)
- Trial name
- INTEGRATEIIa (NCT02773524)
- Testing
- Regorafenib
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 250 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
This is a multicenter, open-label, single-arm phase II study evaluating the efficacy and safety of mannatide in combination with CAPOX chemotherapy and tislelizumab as first-line treatment for patients with recurrent or…
- Trial name
- NCT07655661
- Testing
- Oxaliplatin, Capecitabine, Tislelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Ming Liu
Stomach Neoplasms
Docetaxel and Oxaliplatin in Gastric Cancer
This phase II study addressed the use of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced…
- Trial name
- NCT00382720
- Testing
- Docetaxel + Oxaliplatin, Docetaxel + Oxaliplatin + 5-FU, Docetaxel + Oxaliplatin + Capecitabine
- Where
- 12 sites in United States, Belgium and 10 more
- Volunteers
- 275 people
- Sponsor
- Sanofi